Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
A Phase 1, an Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 (RVT-2001) for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: H3B-8800 (RVT-2001)
Eligibility
Inclusion Criteria:
1. Confirmed diagnosis of MDS, CMML, or AML.
For the MDS Expansion cohort, participants must be lower-risk MDS, defined as low or
intermediate-1 risk categorization per International Prognostic Scoring System (IPSS)
criteria that carries a missense SF3B1 mutation.
For the Dose Optimization cohort, participants must be transfusion-dependent,
lower-risk MDS, defined as very-low to intermediate risk categorization per IPSS-R
criteria that carries a missense SF3B1 mutation.
2. Participants must meet the following criteria relevant to their specific diagnosis:
A. Participants with higher-risk MDS/CMML must be intolerant of hypomethylating agents
(HMAs) or not have responded to 4 treatment cycles of decitabine or 6 treatment cycles
of azacitidine, or must have progressed at any point after initiation of an HMA.
B. For the Dose Escalation portion, participants with lower-risk MDS/CMML must be
transfusion-dependent for red blood cells or platelets.
For the MDS expansion cohort, lower risk MDS participants must be RBC transfusion
dependent according to IWG 2006 criteria and must also have failed erythropoiesis
stimulating agents (ESA) or have serum erythropoietin (EPO) levels greater than (>)
500 units per liter (U/L).
C. For the Dose Optimization cohort, lower-risk MDS participants must be RBC
transfusion-dependent at baseline defined as ≥3 RBC units (concentrates) in 16-weeks
in at least 2 transfusion episodes prior to the first dose of H3B-8800 (RVT-2001) and
must also have failed ESA or have serum EPO levels > 500 U/L. Any ESA use should be
discontinued ≥6 weeks prior to enrollment.
D. Participants with AML must either refuse or not be considered candidates for
intensive induction chemotherapy using consensus criteria for defining such
participants.
E. Participants with CMML must have been treated with at least one prior therapy
(hydroxyurea or a hypomethylating agent [HMA]).
3. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.
4. For MDS expansion and Dose optimization cohorts - absolute neutrophil count (ANC)
greater than or equal to (>=) 500/ microliter (mcL) (0.5*10^9/L).
5. For expansion and Dose optimization cohorts- platelet count >50,000/mcL (50*10^9/L).
6. For Dose-optimization cohort: No prior HMA or lenalidomide in participants with
lower-risk MDS.
7. Adequate baseline organ function.
Exclusion Criteria:
1. Diagnosis of a core binding factor leukemia (t(8;21), t(16;16) or inv(16)). Diagnosis
of acute promyelocytic leukemia (t(15;17))
2. Participants are deemed candidate for hematopoietic stem cell transplants at the time
of enrollment (for AML participants only).
3. Known prior or current retinal or optic nerve disease (example, Retinitis Pigmentosa,
diabetic retinopathy, optic neuritis) not stable for at least 6 months.
4. History of clinically significant, uncorrected vitamin B12 or folate deficiency.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Anousheh Afjei
650-723-8594
I'm interested
Psoriasis Clinical Trials
A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
A Phase 1, an Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 (RVT-2001) for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: H3B-8800 (RVT-2001)
Eligibility
Inclusion Criteria:
1. Confirmed diagnosis of MDS, CMML, or AML.
For the MDS Expansion cohort, participants must be lower-risk MDS, defined as low or
intermediate-1 risk categorization per International Prognostic Scoring System (IPSS)
criteria that carries a missense SF3B1 mutation.
For the Dose Optimization cohort, participants must be transfusion-dependent,
lower-risk MDS, defined as very-low to intermediate risk categorization per IPSS-R
criteria that carries a missense SF3B1 mutation.
2. Participants must meet the following criteria relevant to their specific diagnosis:
A. Participants with higher-risk MDS/CMML must be intolerant of hypomethylating agents
(HMAs) or not have responded to 4 treatment cycles of decitabine or 6 treatment cycles
of azacitidine, or must have progressed at any point after initiation of an HMA.
B. For the Dose Escalation portion, participants with lower-risk MDS/CMML must be
transfusion-dependent for red blood cells or platelets.
For the MDS expansion cohort, lower risk MDS participants must be RBC transfusion
dependent according to IWG 2006 criteria and must also have failed erythropoiesis
stimulating agents (ESA) or have serum erythropoietin (EPO) levels greater than (>)
500 units per liter (U/L).
C. For the Dose Optimization cohort, lower-risk MDS participants must be RBC
transfusion-dependent at baseline defined as ≥3 RBC units (concentrates) in 16-weeks
in at least 2 transfusion episodes prior to the first dose of H3B-8800 (RVT-2001) and
must also have failed ESA or have serum EPO levels > 500 U/L. Any ESA use should be
discontinued ≥6 weeks prior to enrollment.
D. Participants with AML must either refuse or not be considered candidates for
intensive induction chemotherapy using consensus criteria for defining such
participants.
E. Participants with CMML must have been treated with at least one prior therapy
(hydroxyurea or a hypomethylating agent [HMA]).
3. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.
4. For MDS expansion and Dose optimization cohorts - absolute neutrophil count (ANC)
greater than or equal to (>=) 500/ microliter (mcL) (0.5*10^9/L).
5. For expansion and Dose optimization cohorts- platelet count >50,000/mcL (50*10^9/L).
6. For Dose-optimization cohort: No prior HMA or lenalidomide in participants with
lower-risk MDS.
7. Adequate baseline organ function.
Exclusion Criteria:
1. Diagnosis of a core binding factor leukemia (t(8;21), t(16;16) or inv(16)). Diagnosis
of acute promyelocytic leukemia (t(15;17))
2. Participants are deemed candidate for hematopoietic stem cell transplants at the time
of enrollment (for AML participants only).
3. Known prior or current retinal or optic nerve disease (example, Retinitis Pigmentosa,
diabetic retinopathy, optic neuritis) not stable for at least 6 months.
4. History of clinically significant, uncorrected vitamin B12 or folate deficiency.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Anousheh Afjei
650-723-8594
I'm interested
Dermatology Clinical Trials
A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
A Phase 1, an Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 (RVT-2001) for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: H3B-8800 (RVT-2001)
Eligibility
Inclusion Criteria:
1. Confirmed diagnosis of MDS, CMML, or AML.
For the MDS Expansion cohort, participants must be lower-risk MDS, defined as low or
intermediate-1 risk categorization per International Prognostic Scoring System (IPSS)
criteria that carries a missense SF3B1 mutation.
For the Dose Optimization cohort, participants must be transfusion-dependent,
lower-risk MDS, defined as very-low to intermediate risk categorization per IPSS-R
criteria that carries a missense SF3B1 mutation.
2. Participants must meet the following criteria relevant to their specific diagnosis:
A. Participants with higher-risk MDS/CMML must be intolerant of hypomethylating agents
(HMAs) or not have responded to 4 treatment cycles of decitabine or 6 treatment cycles
of azacitidine, or must have progressed at any point after initiation of an HMA.
B. For the Dose Escalation portion, participants with lower-risk MDS/CMML must be
transfusion-dependent for red blood cells or platelets.
For the MDS expansion cohort, lower risk MDS participants must be RBC transfusion
dependent according to IWG 2006 criteria and must also have failed erythropoiesis
stimulating agents (ESA) or have serum erythropoietin (EPO) levels greater than (>)
500 units per liter (U/L).
C. For the Dose Optimization cohort, lower-risk MDS participants must be RBC
transfusion-dependent at baseline defined as ≥3 RBC units (concentrates) in 16-weeks
in at least 2 transfusion episodes prior to the first dose of H3B-8800 (RVT-2001) and
must also have failed ESA or have serum EPO levels > 500 U/L. Any ESA use should be
discontinued ≥6 weeks prior to enrollment.
D. Participants with AML must either refuse or not be considered candidates for
intensive induction chemotherapy using consensus criteria for defining such
participants.
E. Participants with CMML must have been treated with at least one prior therapy
(hydroxyurea or a hypomethylating agent [HMA]).
3. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.
4. For MDS expansion and Dose optimization cohorts - absolute neutrophil count (ANC)
greater than or equal to (>=) 500/ microliter (mcL) (0.5*10^9/L).
5. For expansion and Dose optimization cohorts- platelet count >50,000/mcL (50*10^9/L).
6. For Dose-optimization cohort: No prior HMA or lenalidomide in participants with
lower-risk MDS.
7. Adequate baseline organ function.
Exclusion Criteria:
1. Diagnosis of a core binding factor leukemia (t(8;21), t(16;16) or inv(16)). Diagnosis
of acute promyelocytic leukemia (t(15;17))
2. Participants are deemed candidate for hematopoietic stem cell transplants at the time
of enrollment (for AML participants only).
3. Known prior or current retinal or optic nerve disease (example, Retinitis Pigmentosa,
diabetic retinopathy, optic neuritis) not stable for at least 6 months.
4. History of clinically significant, uncorrected vitamin B12 or folate deficiency.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Anousheh Afjei
650-723-8594
I'm interested
Pediatric Dermatology Clinical Trials
A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
A Phase 1, an Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 (RVT-2001) for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: H3B-8800 (RVT-2001)
Eligibility
Inclusion Criteria:
1. Confirmed diagnosis of MDS, CMML, or AML.
For the MDS Expansion cohort, participants must be lower-risk MDS, defined as low or
intermediate-1 risk categorization per International Prognostic Scoring System (IPSS)
criteria that carries a missense SF3B1 mutation.
For the Dose Optimization cohort, participants must be transfusion-dependent,
lower-risk MDS, defined as very-low to intermediate risk categorization per IPSS-R
criteria that carries a missense SF3B1 mutation.
2. Participants must meet the following criteria relevant to their specific diagnosis:
A. Participants with higher-risk MDS/CMML must be intolerant of hypomethylating agents
(HMAs) or not have responded to 4 treatment cycles of decitabine or 6 treatment cycles
of azacitidine, or must have progressed at any point after initiation of an HMA.
B. For the Dose Escalation portion, participants with lower-risk MDS/CMML must be
transfusion-dependent for red blood cells or platelets.
For the MDS expansion cohort, lower risk MDS participants must be RBC transfusion
dependent according to IWG 2006 criteria and must also have failed erythropoiesis
stimulating agents (ESA) or have serum erythropoietin (EPO) levels greater than (>)
500 units per liter (U/L).
C. For the Dose Optimization cohort, lower-risk MDS participants must be RBC
transfusion-dependent at baseline defined as ≥3 RBC units (concentrates) in 16-weeks
in at least 2 transfusion episodes prior to the first dose of H3B-8800 (RVT-2001) and
must also have failed ESA or have serum EPO levels > 500 U/L. Any ESA use should be
discontinued ≥6 weeks prior to enrollment.
D. Participants with AML must either refuse or not be considered candidates for
intensive induction chemotherapy using consensus criteria for defining such
participants.
E. Participants with CMML must have been treated with at least one prior therapy
(hydroxyurea or a hypomethylating agent [HMA]).
3. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.
4. For MDS expansion and Dose optimization cohorts - absolute neutrophil count (ANC)
greater than or equal to (>=) 500/ microliter (mcL) (0.5*10^9/L).
5. For expansion and Dose optimization cohorts- platelet count >50,000/mcL (50*10^9/L).
6. For Dose-optimization cohort: No prior HMA or lenalidomide in participants with
lower-risk MDS.
7. Adequate baseline organ function.
Exclusion Criteria:
1. Diagnosis of a core binding factor leukemia (t(8;21), t(16;16) or inv(16)). Diagnosis
of acute promyelocytic leukemia (t(15;17))
2. Participants are deemed candidate for hematopoietic stem cell transplants at the time
of enrollment (for AML participants only).
3. Known prior or current retinal or optic nerve disease (example, Retinitis Pigmentosa,
diabetic retinopathy, optic neuritis) not stable for at least 6 months.
4. History of clinically significant, uncorrected vitamin B12 or folate deficiency.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Anousheh Afjei
650-723-8594
I'm interested
A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
A Phase 1, an Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 (RVT-2001) for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: H3B-8800 (RVT-2001)
Eligibility
Inclusion Criteria:
1. Confirmed diagnosis of MDS, CMML, or AML.
For the MDS Expansion cohort, participants must be lower-risk MDS, defined as low or
intermediate-1 risk categorization per International Prognostic Scoring System (IPSS)
criteria that carries a missense SF3B1 mutation.
For the Dose Optimization cohort, participants must be transfusion-dependent,
lower-risk MDS, defined as very-low to intermediate risk categorization per IPSS-R
criteria that carries a missense SF3B1 mutation.
2. Participants must meet the following criteria relevant to their specific diagnosis:
A. Participants with higher-risk MDS/CMML must be intolerant of hypomethylating agents
(HMAs) or not have responded to 4 treatment cycles of decitabine or 6 treatment cycles
of azacitidine, or must have progressed at any point after initiation of an HMA.
B. For the Dose Escalation portion, participants with lower-risk MDS/CMML must be
transfusion-dependent for red blood cells or platelets.
For the MDS expansion cohort, lower risk MDS participants must be RBC transfusion
dependent according to IWG 2006 criteria and must also have failed erythropoiesis
stimulating agents (ESA) or have serum erythropoietin (EPO) levels greater than (>)
500 units per liter (U/L).
C. For the Dose Optimization cohort, lower-risk MDS participants must be RBC
transfusion-dependent at baseline defined as ≥3 RBC units (concentrates) in 16-weeks
in at least 2 transfusion episodes prior to the first dose of H3B-8800 (RVT-2001) and
must also have failed ESA or have serum EPO levels > 500 U/L. Any ESA use should be
discontinued ≥6 weeks prior to enrollment.
D. Participants with AML must either refuse or not be considered candidates for
intensive induction chemotherapy using consensus criteria for defining such
participants.
E. Participants with CMML must have been treated with at least one prior therapy
(hydroxyurea or a hypomethylating agent [HMA]).
3. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.
4. For MDS expansion and Dose optimization cohorts - absolute neutrophil count (ANC)
greater than or equal to (>=) 500/ microliter (mcL) (0.5*10^9/L).
5. For expansion and Dose optimization cohorts- platelet count >50,000/mcL (50*10^9/L).
6. For Dose-optimization cohort: No prior HMA or lenalidomide in participants with
lower-risk MDS.
7. Adequate baseline organ function.
Exclusion Criteria:
1. Diagnosis of a core binding factor leukemia (t(8;21), t(16;16) or inv(16)). Diagnosis
of acute promyelocytic leukemia (t(15;17))
2. Participants are deemed candidate for hematopoietic stem cell transplants at the time
of enrollment (for AML participants only).
3. Known prior or current retinal or optic nerve disease (example, Retinitis Pigmentosa,
diabetic retinopathy, optic neuritis) not stable for at least 6 months.
4. History of clinically significant, uncorrected vitamin B12 or folate deficiency.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Anousheh Afjei
650-723-8594
I'm interested
A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
A Phase 1, an Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 (RVT-2001) for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: H3B-8800 (RVT-2001)
Eligibility
Inclusion Criteria:
1. Confirmed diagnosis of MDS, CMML, or AML.
For the MDS Expansion cohort, participants must be lower-risk MDS, defined as low or
intermediate-1 risk categorization per International Prognostic Scoring System (IPSS)
criteria that carries a missense SF3B1 mutation.
For the Dose Optimization cohort, participants must be transfusion-dependent,
lower-risk MDS, defined as very-low to intermediate risk categorization per IPSS-R
criteria that carries a missense SF3B1 mutation.
2. Participants must meet the following criteria relevant to their specific diagnosis:
A. Participants with higher-risk MDS/CMML must be intolerant of hypomethylating agents
(HMAs) or not have responded to 4 treatment cycles of decitabine or 6 treatment cycles
of azacitidine, or must have progressed at any point after initiation of an HMA.
B. For the Dose Escalation portion, participants with lower-risk MDS/CMML must be
transfusion-dependent for red blood cells or platelets.
For the MDS expansion cohort, lower risk MDS participants must be RBC transfusion
dependent according to IWG 2006 criteria and must also have failed erythropoiesis
stimulating agents (ESA) or have serum erythropoietin (EPO) levels greater than (>)
500 units per liter (U/L).
C. For the Dose Optimization cohort, lower-risk MDS participants must be RBC
transfusion-dependent at baseline defined as ≥3 RBC units (concentrates) in 16-weeks
in at least 2 transfusion episodes prior to the first dose of H3B-8800 (RVT-2001) and
must also have failed ESA or have serum EPO levels > 500 U/L. Any ESA use should be
discontinued ≥6 weeks prior to enrollment.
D. Participants with AML must either refuse or not be considered candidates for
intensive induction chemotherapy using consensus criteria for defining such
participants.
E. Participants with CMML must have been treated with at least one prior therapy
(hydroxyurea or a hypomethylating agent [HMA]).
3. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.
4. For MDS expansion and Dose optimization cohorts - absolute neutrophil count (ANC)
greater than or equal to (>=) 500/ microliter (mcL) (0.5*10^9/L).
5. For expansion and Dose optimization cohorts- platelet count >50,000/mcL (50*10^9/L).
6. For Dose-optimization cohort: No prior HMA or lenalidomide in participants with
lower-risk MDS.
7. Adequate baseline organ function.
Exclusion Criteria:
1. Diagnosis of a core binding factor leukemia (t(8;21), t(16;16) or inv(16)). Diagnosis
of acute promyelocytic leukemia (t(15;17))
2. Participants are deemed candidate for hematopoietic stem cell transplants at the time
of enrollment (for AML participants only).
3. Known prior or current retinal or optic nerve disease (example, Retinitis Pigmentosa,
diabetic retinopathy, optic neuritis) not stable for at least 6 months.
4. History of clinically significant, uncorrected vitamin B12 or folate deficiency.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Anousheh Afjei
650-723-8594
I'm interested